logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5655.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5655.produseast1
Showing 1 - 20 of 45 Items
Showing 1 - 20 of 45 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Retention on antiretroviral therapy and drivers of lost‐to‐follow up in the Central African Republic: a longitudinal analysis

Tekpa G, Inikoutiyo J, Yonli C, Noguera C, Lujwiro PP,  et al.
2024-12-01 • Journal of the International AIDS Society
2024-12-01 • Journal of the International AIDS Society

INTRODUCTION

The retention in care of patients undergoing antiretroviral therapy (ART) is a cornerstone for preventing AIDS‐associated morbidity and mortality, as well as furthe...

Journal Article
|
Research
Journal Article
|
Review

Cohort profile: the Khayelitsha antiretroviral programme, Cape Town, South Africa

Stinson K, Goemaere E, Coetzee D, van Cutsem G, Hilderbrand K,  et al.
2016-05-20 • International Journal of Epidemiology
Journal Article
|
Commentary
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Commentary
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Commentary
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Letter
Journal Article
|
Commentary

HIV and Ebola virus: two jumped species but not two of a kind

Calmy A, Goemaere E, van Cutsem G
2015-08-24 • AIDS
2015-08-24 • AIDS
Journal Article
|
Commentary
Journal Article
|
Commentary
Journal Article
|
Research
Journal Article
|
Letter

Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy

Boulle A, van Cutsem G, Cohen K, Hilderbrand K, Mathee S,  et al.
2008-08-06 • JAMA
2008-08-06 • JAMA
CONTEXT
Rifampicin-based antitubercular therapy reduces the plasma concentrations of nevirapine and efavirenz. The virological consequences of these interactions are not well describ...
2016-05-20 • International Journal of Epidemiology

Why it's time to say goodbye to Stavudine...everywhere

Andrieux-Meyer I, Clayden P, Collins S, Geffen N, Goemaere E,  et al.
2012-03-01 • Southern African Journal of HIV medicine
2012-03-01 • Southern African Journal of HIV medicine

Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans Frontières

Tassie JM, Szumilin E, Calmy A, Goemaere E
2003-09-05 • AIDS
2003-09-05 • AIDS
We describe the short-term results of highly active antiretroviral therapy (HAART) in seven projects in low and middle income countries. A total of 743 adults were included, and clinical...

Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa

Chu KM, Boulle AM, Ford NP, Goemaere E, Asselman V,  et al.
2010-02-17 • PLOS One
2010-02-17 • PLOS One
BACKGROUND: The majority of antiretroviral treatment programmes in sub-Saharan Africa are scaling up antiretroviral treatment using a fixed dose first-line antiretroviral regimen contain...

Rational use of moxifloxacin for tuberculosis treatment

Cox HS, Ford NP, Keshavjee S, McDermid C, von Schoen-Angerer T,  et al.
2011-04-01 • Lancet Infectious Diseases
2011-04-01 • Lancet Infectious Diseases

Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial

Rangaka MX, Wilkinson RJ, Boulle AM, Glynn JR, Fielding K,  et al.
2014-05-14 • Lancet
2014-05-14 • Lancet
Antiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more common in people with HIV than in people without HIV. We aimed to assess the effect of isoniazid prevent...

Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa

Cox HS, Hughes J, Daniels J, Azevedo VD, McDermid C,  et al.
2014-04-01 • International Journal of Tuberculosis and Lung Disease
2014-04-01 • International Journal of Tuberculosis and Lung Disease
SETTING: Khayelitsha, South Africa, a peri-urban township with high burdens of tuberculosis (TB), drug-resistant tuberculosis (DR-TB), and human immunodeficiency virus (HIV) infection.

Highly active antiretroviral therapy in resource-poor settings: the experience of Medecins Sans Frontieres

Tassie JM, Szumilin E, Calmy A, Goemaere E
2003-09-01 • AIDS
2003-09-01 • AIDS
We describe the short-term results of highly active antiretroviral therapy (HAART) in seven projects in low and middle income countries. A total of 743 adults were included, and clinical...

The continuing burden of advanced HIV disease over 10 years of increasing antiretroviral therapy coverage in South Africa

Osler M, Hilderbrand K, Goemaere E, Ford NP, Smith M,  et al.
2018-03-04 • Clinical Infectious Diseases
2018-03-04 • Clinical Infectious Diseases
BACKGROUND
Antiretroviral treatment (ART) has been massively scaled up to decrease human immunodeficiency virus (HIV)-related morbidity, mortality, and HIV transmission. However, des...

The need to accelerate access to new drugs for multidrug-resistant tuberculosis

Cox HS, Furin J, Mitnick CD, Daniels C, Cox V,  et al.
2015-07-01 • Bulletin of the World Health Organization
2015-07-01 • Bulletin of the World Health Organization
Approximately half a million people are thought to develop multidrug-resistant tuberculosis annually. Barely 20% of these people currently receive recommended treatment and only about 10...

The Epidemiology, Pathogenesis, Transmission, Diagnosis, and Management of Multidrug-Resistant, Extensively Drug-Resistant, and Incurable Tuberculosis

Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R,  et al.
2017-03-15 • Lancet Respiratory Medicine
2017-03-15 • Lancet Respiratory Medicine
Global tuberculosis incidence has declined marginally over the past decade, and tuberculosis remains out of control in several parts of the world including Africa and Asia. Although tube...

Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa

Boulle AM, van Cutsem G, Hilderbrand K, Cragg C, Abrahams M,  et al.
2010-02-20 • AIDS
2010-02-20 • AIDS
OBJECTIVES: We report on outcomes after 7 years of a community-based antiretroviral therapy (ART) programme in Khayelitsha, South Africa, with death registry linkages to correct for mort...

Linezolid for multidrug-resistant tuberculosis

Cox HS, Ford NP, Hughes J, Goemaere E
2013-01-01 • Lancet Infectious Diseases
2013-01-01 • Lancet Infectious Diseases

Preferred antiretroviral drugs for the next decade of scale up

Andrieux-Meyer I, Calmy A, Cahn P, Clayden P, Raguin G,  et al.
2012-09-18 • Journal of the International AIDS Society
2012-09-18 • Journal of the International AIDS Society
Global commitments aim to provide antiretroviral therapy (ART) to 15 million people living with HIV by 2015, and recent studies have demonstrated the potential for widespread ART to prev...

Paediatric HIV Treatment Failure: A Silent Epidemic

Bernheimer J, Patten GE, Makeleni T, Mantangana N, Dumile N,  et al.
2015-07-23 • Journal of the International AIDS Society
2015-07-23 • Journal of the International AIDS Society
Paediatric antiretroviral treatment (ART) failure is an under-recognized issue that receives inadequate attention in the field of paediatrics and within HIV treatment programmes. With pa...

Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa

Coetzee D, Hildebrand K, Boulle AM, Maartens G, Louis F,  et al.
2004-04-09 • AIDS
2004-04-09 • AIDS
BACKGROUND
A community-based antiretroviral therapy (ART) programme was established in 2001 in a South African township to explore the operational issues involved in providing ART in...

The enduring burden of advanced human immunodeficiency virus disease

Ford NP, Goemaere E, Hildebrand K, Perez-Casas C
2020-05-05 • Clinical Infectious Diseases
2020-05-05 • Clinical Infectious Diseases